Skip to main content

Novartis vs Roche: Revenue, Profit and Business Model

Novartis had $56.7B of annual revenue in FY2025 and $14B of net income. Roche had ~$76B of annual revenue in FY2025 and ~$15.5B of net income.

Latest financial snapshot

Novartis

Latest annual revenue
$56.7B (FY2025)
Net income
$14B
Net margin
24.7%
Revenue growth
+6.5% a year, FY2021–FY2025

Roche

Latest annual revenue
~$76B (FY2025)
Net income
~$15.5B
Net margin
20.3%
Revenue growth
-1.0% a year, FY2021–FY2025

Financial summary

Novartis

Novartis grew FY2025 net sales 8% to $54.5 billion with a core operating margin above 40% and free cash flow of $17.6 billion. 2026 is a reset year: US generics of Entresto and Promacta cut Q1 2026 net sales 5% at constant currencies to $13.1 billion and core operating income 14%. Q2 2026 net sales rose 1% cc to $14.4 billion with a 41.2% core margin, though net income fell 19%. Management guides for low single-digit sales growth and a low single-digit decline in core operating income for 2026 at constant currencies. Novartis is a Swiss multinational pharmaceutical corporation with a market valuation generally exceeding $200 billion.

Roche

Roche's 2025 group sales were ~$73.8 billion (CHF 61.5 billion), up 7% at constant exchange rates but only 2% in Swiss francs. Core operating profit grew 13% CER to ~$26.2 billion (CHF 21.8 billion), core EPS was CHF 19.46, and IFRS net income jumped to ~$16.6 billion (CHF 13.8 billion) from ~$11 billion (CHF 9.2 billion) in 2024, when impairments depressed profit. In H1 2026 core operating margin widened 1.7 points to 39.0%, while a strong franc pushed reported sales down 2%. The board raised the dividend to CHF 9.80, the 39th consecutive increase, and guided for mid-single-digit CER sales growth and high-single-digit core EPS growth in 2026. F. Hoffmann-La Roche AG is a colossal Swiss multinational healthcare company operating heavily under two massive divisions: Pharmaceuticals and Diagnostics, sustaining a market valuation generally exceeding $250 billion.

Revenue and profit by year

Novartis

Novartis revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$56.7B$14B24.7%+9.6%Source
FY2024$51.7B$11.9B23.1%+10.8%Source
FY2023$46.7B$14.8B31.8%+7.4%Source
FY2022$43.5B$7B16.0%-1.2%Source
FY2021$44B$24B54.6%—Source
Full Novartis financials

Roche

Roche revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025~$76B~$15.5B20.3%+1.5%Source
FY2024~$74.9B~$9.9B13.3%+3.2%Source
FY2023~$72.5B~$13.8B19.0%-8.2%Source
FY2022~$79B~$14.9B18.9%-0.1%Source
FY2021~$79B~$16.7B21.2%—Source
Full Roche financials

Where the revenue comes from

Novartis

  • Cardiovascular, Renal, And MetabolicMajor

    Medicines such as Entresto and Leqvio sold through specialist and primary-care channels.

  • OncologyMajor

    Cancer medicines and radioligand therapies including Kisqali, Pluvicto, and Scemblix.

  • ImmunologyMajor

    Autoimmune and inflammatory disease products, including Cosentyx.

  • NeuroscienceMaterial

    Neurology products including Kesimpta and related pipeline programs.

  • Established Brands And Other Medicines

    Complementary

    Remaining prescription medicines sold across global markets.

Roche

  • Prescription medicines
  • Biologics and oncology drugs
  • Diagnostic instruments
  • Diagnostic reagents and tests
  • Sequencing and molecular diagnostics
  • Clinical data and companion diagnostics

Business model and strategy

Novartis

How it makes money

Novartis AG is a focused innovative medicines company headquartered in Basel, Switzerland, that discovers, manufactures, and markets transformative therapeutics across four core therapeutic areas: Cardiovascular, Renal and Metabolic (CRM), Immunology, Neuroscience, and Oncology.

Growth strategy

Novartis concentrates on four therapeutic areas and on the US, its largest market. It pairs internal research with bolt-on acquisitions of late-stage or platform biotechs: Chinook (2023, kidney disease), MorphoSys (2024, myelofibrosis), Kate Therapeutics (2024, gene therapy capsids) and Avidity Biosciences (closed February 27, 2026, about $12 billion, neuromuscular RNA medicines).

Competitive advantage

Novartis's economic moat is anchored by its pioneering leadership in advanced technology platforms—specifically radioligand therapies and gene therapy manufacturing—and Entresto's entrenched global standard-of-care position in heart failure.

Novartis business model in full

Roche

How it makes money

F. Hoffmann-La Roche AG (Roche Group) is a Swiss multinational healthcare pioneer that operates an integrated model combining targeted pharmaceuticals with in-vitro medical diagnostics. The company functions through two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals division develops innovative medicines in oncology (Perjeta, Kadcyla, Phesgo for HER2-positive breast cancer;

Growth strategy

Roche is building a cardiovascular, renal and metabolic franchise through acquisitions of Carmot Therapeutics (2023, $2.7 billion upfront) and 89bio (2025, up to about $3.5 billion), the petrelintide partnership with Zealand Pharma, and a new Innovation Center in Boston opened in September 2026.

Competitive advantage

Roche's durable competitive moat is underpinned by the synergistic union of in-vitro diagnostics and targeted biopharmaceuticals, creating the global benchmark for personalized healthcare.

Roche business model in full

Questions about Novartis vs Roche

Which company has higher revenue — Novartis AG or F. Hoffmann-La Roche AG?

Novartis AG had $56.7B (FY2025), while F. Hoffmann-La Roche AG had ~$76B (FY2025). By latest annual revenue, F. Hoffmann-La Roche AG is the larger business, with Novartis AG showing a smaller revenue base.

What is the market cap of Novartis AG vs F. Hoffmann-La Roche AG?

Novartis AG's market capitalisation stands at $275.3B, while F. Hoffmann-La Roche AG's is $355.0B. F. Hoffmann-La Roche AG carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Novartis AG.

How does revenue per employee compare for Novartis AG and F. Hoffmann-La Roche AG?

Novartis AG has $753k / employee in revenue per employee, while F. Hoffmann-La Roche AG has $674k / employee. Headcounts may use different dates, so the ratio alone does not establish which business operates more efficiently.

How do Novartis AG and F. Hoffmann-La Roche AG make money?

Novartis AG and F. Hoffmann-La Roche AG generate revenue in fundamentally different ways. Novartis AG: Novartis AG is a focused innovative medicines company headquartered in Basel, Switzerland, that discovers, manufactures, and markets transformative therapeutics across four core therapeutic areas: Cardiovascular, Renal and Metabolic (CRM), Immunology, Neuroscience, and Oncology. F. Hoffmann-La Roche AG: F.

Which company is valued higher relative to revenue — Novartis AG or F. Hoffmann-La Roche AG?

On a price-to-sales (P/S) basis, Novartis AG trades at 4.9x P/S and F. Hoffmann-La Roche AG at 4.7x P/S. Novartis AG commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to F. Hoffmann-La Roche AG. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.

Is Novartis AG bigger than F. Hoffmann-La Roche AG?

By last reported revenue, F. Hoffmann-La Roche AG (~$76B (FY2025)) is the larger company compared to Novartis AG ($56.7B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Novartis vs Roche overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.